Screener
Crinetics Pharmaceuticals CRNX Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Collaboration and license revenue | 428 | 361 |
| Total revenue | 10,734 | 361 |
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's total cost of revenue?
- Crinetics Pharmaceuticals (CRNX) reported total cost of revenue of $200K in Q1 2026.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Crinetics Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude